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Abstract
It is a common practice to perform a separate analysis of efficacy and safety 
data from clinical trials to estimate the benefit and risk aspects of a particular 
treatment regimen. However, by doing so, one is likely to miss the complete 
picture of the treatment effect given that these data are generated from the 
same study subjects and therefore most likely will be correlated. Therefore, it is 
desirable to analyze these data jointly to obtain a more complete profile of the 
treatment regimen. A substantial number of statistical methodologies have been 
proposed in the last decade to model the time-to-event data and longitudinal 
repeated measures jointly. These methods provide better insights to understand 
the treatment effect in time-to-event data by incorporating the information 
contained in the longitudinal repeated measures. In this article, we utilize the 
joint model method to analyze the time-to-event data, such as patient overall 
survival, and the repeated measures of laboratory test data to better estimate 
the treatment effect of a regimen. The data from a recent oncology clinical trial 
is used to illustrate the application of our proposed method. 
Keywords: Joint modeling; Time-to-event data; Longitudinal repeated 
measures; Controlled clinical trials
Introduction
During the course of a clinical trial, several types of data are 
usually collected. This includes data to investigate the efficacy of 
the intervention of a test drug, the demographic data of the subjects 
under study, the laboratory data to understand the pharmacological 
effect of the treatment on the body, and the possible adverse effects, 
etc. Conventionally, it is common practice to analyze the efficacy and 
safety data separately to estimate the benefit and risk aspects of the 
treatment regimen. However, by performing separate analysis, one is 
likely to miss the complete picture of the treatment effect given that 
these data are generated from the same study subjects and therefore 
most likely will be correlated.
For example, in cancer clinical trials to study patient survival 
after treatment, patients are usually given treatment which can 
substantially cause neutropenia, namely, the reduction of white blood 
cells. Severe neutropenia can lead to infection or sepsis which can 
in turn lead to other complications that affect patient’s survival. This 
indirect treatment effect usually is not captured during the efficacy 
analysis alone. Therefore, it is more desirable to analyze these data 
together to obtain a more complete profile of the treatment regimen. 
Similar strategies have also been implemented in the study of HIV, 
neuroscience, and prostate cancers, just to name a few. In the 
following, we will focus our attention on the analysis of survival data 
and repeated measures of laboratory parameters such as white blood 
cell counts and other adverse effects. 
A substantial number of statistical methodologies have been 
proposed in the last decade to model the time-to-event data and 
longitudinal repeated measures jointly. For example, Tsiatis et al. 
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[1] in the study of AIDS, Diggle [2] in the study of patients with 
schizophrenia symptoms, Henderson, et al. [3] studied the positive 
and negative symptom scale in neuroscience, and Law et al. [4] in the 
study of disease progression biomarkers, etc.
Using parametric or semi-parametric maximum likelihood or 
and Bayesian methods, these authors estimated the parameters for 
both the longitudinal and event processes and used the associated 
asymptotic properties of the estimates. They also showed that the 
estimates from the joint model can usually be more efficient than the 
estimates from the separate models.
In this article, we utilize the joint model method to analyze 
the patient overall survival incorporating the laboratory data 
of neutrophils counts to better estimate the treatment effect 
of an experimental cancer therapy. We describe the statistical 
methodologies about joint modeling in section 2 followed by the 
parameter estimation and model diagnostics in section 3. In section 
4, we illustrate the applications of these methods to the data from a 
recent cancer drug study. We conclude our paper with discussion in 
section 5.
Joint Modeling Methods
Let Ti denote the observed failure time for the i-th subject 
(i=1,…,n), which is taken as the minimum of the true event time *iT
and the censoring time Ci, namely, 
*( ; )i i iT min T C= . Furthermore, we 
define the event indicator as *( )i i iI T Cδ = < , where I(.) is the indicator 
function that takes the value 1 if the condition *i iT C< is satisfied, and 
0 otherwise. Thus, the observed data for the time-to-event outcome 
consist of the pairs {(Ti,{(Ti,δi),i=1,…,n}. 
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For the longitudinal responses, let yi(t) denote the value of the 
longitudinal outcome at time point t for the i-th subject. We should 
note here that we do not actually observe yi(t) at all time points, 
but only at the very specific occasions tij at which measurements 
were taken. Thus, the observed longitudinal data consists of the 
measurements yij={yi(tij), j=1,…,ni}.
As in many clinical trials, data could be measured with errors due 
to the limitation of instruments and quantifications. That is especially 
true for the laboratory data. Therefore, as a general setting, we assume 
the following relationship between the observed value yi(t) and the 
true underlying unobserved value mi(t): 
yi(t) =mi(t)+εi,     (1)
where εi is the random error following a continuous distribution 
function. In the following, we will assume εI follows a normal 
distribution for simplicity.
For the event process, we assume the following hazard model: 
'
0( | ) ( ) exp{ },i i ih t w h t wγ=    (2)
where wi is the vector of covariates. One of our aim is to associate 
mi(t) with the event outcome Ti in addition to the vector of covariates 
wi to better estimate the endpoints of interest. 
To quantify the effect of mi(t) on the risk for an event, a commonly 
adopted approach is to use a relative risk model proposed by Therneau 
and Grambsch [5]: 
'
0( | ( ), ) ( ) exp{ ( )},i i i i ih t M t w h t w m tγ α= +  (3)
where Mi(t)={mi(u),0<u<t) denotes the history of the true unobserved 
longitudinal process up to time t, h0(.) denotes the baseline risk 
function, and wi is a vector of baseline covariates (such as a treatment 
indicator, history of diseases, etc.) with a corresponding vector of 
regression coefficients.
In the model above, the parameter α quantifies the effect of the 
underlying longitudinal outcome to the risk for an event in an additive 
manner; for instance, in the example section below, α measures the 
effect of the value of Absolute Neutrophils Counts (ANC) on the risk 
for death due to the fact that a low ANC value is likely to lead to 
infection which can indirectly cause medical complications to affect 
the overall patient survival. 
The baseline risk function h0(.) is typically left unspecified. 
However, within the joint modeling framework, Hsieh, et al. [6] had 
noted that unspecified h0(.) can lead to underestimated standard errors 
of the parameter estimates. To avoid this problem, one can specify the 
function using the Weibull [7], Gamma, or for more flexible models 
in which h0(.) is approximated using step functions or spline-based 
approaches. Alternatively, if the proportionality assumption in (2) or 
(3) fails, one can use the accelerated failure time model. 
In order to incorporate a time dependent covariate within this 
framework, we define the survival function So as 
}{
*
0 0
~ exp ( ) ,
T TS w m s dsγ α+∫    (4)
with the corresponding hazard function for subject i being 
hi(t|Mi(t),wi)=h0{Vi(t)}exp{Twi+αmi(t)}  (5)
where 
*
0
( ) exp{ ( )} .
T T
i i iV t w m s dsγ α= +∫   (6)
An important difference between equations (5) and (3) is that in 
the former the entire covariate history Mi (t) is assumed to influence 
the subject-specific risk (due to the fact that h0(.)  is evaluated at 
Vi(t), whereas in the latter the subject-specific risk depends only 
on the current value of the time-dependent covariate mi(t). The 
survival function for a subject with covariate history Mi(t)} equals 
Si{t|Mi(t)}=S0{Vi(t)}, which means that this subject ages on an 
accelerated schedule Vi(t) compared to S0.
Equation (1) is a general framework of the relationship between 
the observed and true underlying data. The model needs to be 
explicitly specified during the data analysis to take into account the 
intermittent nature of the data collection. Namely, for subject , one 
only observes yij={yi(tij), j=1,…,ni} at a set of time {tij=1,…,ni}.
Assuming the normal error distribution and linear mixed effects 
model to describe the subject-specific longitudinal process, we have 
yi(tij)= mi(tij)+εi(tij)
2( ) ( ) ( ), ( )~ (0, )T Ti ij i ij i i ij i ijx t z t b t t Nβ ε ε σ= + +  (7)
where β denotes the vector of the unknown fixed effects parameters, 
bi denotes a vector of random effects, xi(t) and zi(t) denote row vectors 
of the design matrices for the fixed and random effects, respectively, 
and εi(t)  is the measurement error term, which is assumed to be 
independent of bi and with mean 0 and variance σ2.
Parameter estimation and model diagnostics
Several estimation methods had been proposed for the joint 
modeling, e.g., semiparametric maximum likelihood (Hsieh, et al. [6]; 
Henderson, et al. [3]; Wulfsohn and Tsiatis [8], Tsiatis and Davidian 
[9]) and Bayes methods (Chi and Ibrahim [10]; Brown and Ibrahim 
[11]; Wang and Taylor [8]; Xu and Zeger [12]).
Briefly, the maximum likelihood estimation for joint models is 
based on the maximization of the likelihood corresponding to the 
joint distribution of the time-to-event and longitudinal outcomes 
{Ti,δi,yi}. Since the time-independent random effects bi underlies both 
the longitudinal and survival processes, assume 
( , , | , ) ( , | , ) ( | , )i i i i i i i i if T y b f T b f y bδ θ δ θ θ=  (8)
with 
( | , ) { ( ) | , },i i i ij i
j
f y b f y t bθ θ=Π    (9)
where ' ' ' '( , , )t y bθ θ θ θ=  denotes the parameter vector, with θt denoting 
the parameters for the event time outcome, θy the parameters for the 
longitudinal outcomes, and θb the unique parameters of the random-
effects covariance matrix, and f(.) denotes an appropriate probability 
density function for the longitudinal or event process.
Under the modeling assumptions and the conditional 
independence assumptions in equation (8), assume f{yi(tij)|(bi,θy} 
being the univariate normal density for the longitudinal responses, 
and f(bi,θb) being the multivariate normal density for the random 
effects, the joint log-likelihood contribution for the i-th subject is 
log ( , , , ) log ( , | , , )[ { ( ) | , }] ( , ) ,i i i i i i i i ij i i b i
j
f T y f T b f y t b f b dbδ θ δ θ β θ θ= ∏∫    (10)
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where the likelihood of the event process is 
( , | , , ) { ( | ( ), , )} ( | ( ), , ),ii i i t i i i i t i i i i tf T b h T M T S T M T
δδ θ β θ β θ β=  
      (11)
with hi(.) given by either (3) or (5), and 
*( | ( ), , , ) Pr( | ( ), , , )i i i t i i i tS t M t w T t M t wθ β θ β= >
0
=exp{-- ( | ( ), , ) }.
t
i i th s M s dsθ β∫    (12)
Since the integration in (10) generally has no analytical form, the 
maximization of the log-likelihood function (10) with respect to θ is 
conventionally performed using numerical integration techniques 
such as Gaussian quadrature and Monte Carlo. These approaches 
have been successfully applied in the joint modeling framework by 
various authors mentioned previously.
Residual plots are the conventional methods for model diagnostics 
to verify the appropriateness of the distributional assumptions and 
the adequacy of the model assumed. Model diagnostics for linear 
mixed model and time-to-event model have been well studied in 
the literature. However, given the inter-dependency between the 
longitudinal process and the event process, extra cautions are needed 
on the diagnostics for the joint model. For example, when a subject 
is discontinued the study or died, the data for either process will no 
longer be available.
When the process of subject discontinuation is random, 
the residuals may be less affected than the scenarios when the 
discontinuation was influenced by the failure of treatment and causes 
informative missing data issues. Rizopoulos, et al. [13] proposed 
a method to augment the observed data with randomly imputed 
longitudinal responses. Briefly, based on the parameter estimates 
of the joint model with available data, they performed multiple 
imputation with repeated sampling from the posterior distribution 
of the missing observations given the observed data. The complete 
profile of the longitudinal data can thus be established for each 
subject. The advantage of using the simulated values together with 
the observed data to calculate residuals is that these residuals inherit 
now the properties of the complete data model, and therefore they 
can be directly used in diagnostic plots.
Example
In this section, we present an example from a recent clinical 
trial to illustrate the use of the procedures described above. This is 
a multicenter clinical trial to investigate the treatment effect of an 
experimental medicine on breast cancer. Patients were randomized 
into two groups, treatment and placebo, to study the treatment 
benefit in disease progression. During the trial, the patients’ 
laboratory data on Absolute Neutrophils Counts (ANC) were also 
collected at each treatment visit to monitor the level of neutrophils. 
Low level of neutrophiles can possibly cause infection and lead to 
other complications to affect the patient disease. Even though the 
primary endpoint of the study is the treatment effect on disease 
progression which is usually estimated using efficacy data only, it is 
more informative to understand how the safety aspects of the study 
can also contribute to the patient’s disease progression.
The longitudinal ANC data was analyzed using a linear mixed 
effect model with a random intercept and fixed treatment and visit 
effects. Since the LME model requires the normality assumption, data 
was transformed using the Box-Cox power function to conform to 
the normality assumption. The normal plot after the transformation 
is shown in Figure 1. 
A total of 455 patients were randomized into two treatment 
groups (Group 1 and Group 3) in approximately 2:1 ratio with 204 
events of disease progression and a total of 1745 repeated measures of 
ANC at the end of the study. Some patients had missing measures of 
the ANC during the duration of the clinical study. The patterns of the 
ANC values during the visits for each study are shown in Figure 2 and 
Figure 3, respectively. The boxplots for the treatments by visits are 
also shown in Figure 4. One can easily see substantial ANC values by 
treatment interactions during the course of the study. Therefore, we 
postulate a model for the longitudinal data to include the treatment, 
visit, and their interaction effects.
The Kaplan-Meier curves of survival times for the treatment groups 
is displayed in Figure 5. As common practice, a Cox proportional 
model was utilized to analyze the event data. Prior to performing the 
modeling, the assumption of proportionality was tested and the result 
is shown in Figure 6. The proportionality assumption on treatment 
effect seems to be reasonable judging from the graph.
Figure  1: Box-Cox transformation of ANC values.
Figure 2: ANC level of Group 1.
Austin Biom and Biostat 2(3): id1025 (2015)  - Page - 04
Kao-Tai Tsai Austin Publishing Group
Submit your Manuscript | www.austinpublishinggroup.com
The REML estimates of the mixed effect model with fixed 
treatment, visit, treatment by visit interaction effects and random 
intercept are shown in Table 1. The results indicate both significant 
visit and interaction effects on the values of ANC.
Similarly, the estimate from Cox proportional hazard model with 
treatment as covariate indicates a highly significant treatment effect 
as shown in Table 2.
After the separate LME model on the longitudinal data of ANC 
values and Cox proportional hazard model on the event data was 
fitted, a joint model was fitted using MLE to both the longitudinal 
and event sub-models and the results are shown in Tables 3 & 4.
The treatment effect (0.734) in Table 4 from the joint model is 
larger than that in Table 2 (0.586) from the Cox model alone. The 
value of α in Table 4 has a negative value which reduces the hazard for 
the patients with higher values of ANC, even though the effect of α did 
not reach the 5% significance level. Putting these findings together, 
one can conclude that the treatment effect on ANC indirectly affected 
patient survival. This incremental treatment would not have been 
Figure 3: ANC level of Group 3.
Figure 4: ANC values by treatment and visit.
Figure 5: Kaplan-Meier curve of patient survival data.
Figure  6: Proportional hazard test for treatment.
Covariate Value Std.Error DF t-value p-value
(Intercept) 1.5961 0.0463 1288 34.419 0.000
trt3 -0.1341 0.0801 453 -1.673 0.095
visit -0.1520 0.0069 1288 -21.821 0.000
trt3:visit 0.0824 0.0120 1288 6.820 0.000
Table 1: LME model of ANC with interaction.
Covariate coef exp(coef) se(coef) z Pr(>|Z|)
trt3 0.5869 1.7983 0.1443 4.068 4.74e-05
Table 2: Estimate of cox proportional hazard model.
Covariate Value Std.Err z-value p-value
(Intercept) 1.6008 0.0460 34.7970 < 0.0001
trt3 -0.1312 0.0809 -1.6207 0.1051
visit -0.1515 0.0071 -21.3088 < 0.0001
trt3:visit 0.0803 0.0127 6.3020 < 0.0001
Table 3: Estimates of the longitudinal process.
 Covariate Value Std.Err z-value p-value
trt3 0.7340 0.2544 2.8855 0.0039
α -0.0380 0.0534 -0.7112 0.4769
Table 4: Estimates of the event process.
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detected if one were to analyze the treatment efficacy using only the 
survival data without bringing in the effect from ANC.
To assess the goodness of fit of the proposed model and better 
understand the differences between the treatment groups, we 
examined the difference of the random intercepts and the residuals 
from the fitted model for the groups. The random intercepts for 
the groups were plotted using a Q-Q plot as shown in Figure 7. The 
distributions appear to be similar between these two groups with a 
minor difference in locations; however, this difference does not seem 
to be significant.
The subject-specific residuals ( ( ) ( ) ( ) ( ) )ii ij i ij i ij i ijr t y t x t z t bβ= − −
 
 
and marginal residuals )( i i ir y x β= −

 were plotted against the 
respective fitted values (Figures 8 and 9). The residuals did not seem 
to have any obvious pattern to suspect a lack-of-fit of the proposed 
model except for a minor dip in the left hand side of the subject-
specific residual plot. This could possibly due to the early dropouts of 
some patients who had severe disease at the entry of the clinical study. 
An imputation to ‘re-create’ the missing longitudinal data for these 
scenarios was conducted and the residual plot after the imputation 
seems to alleviate this downward dip to a few degrees but without 
substantial difference.
Figure 7: Comparison of random effects between groups.
Figure  8: Comparison of random effects between groups.
Discussion
Medical intervention can usually produce effects in more than 
one aspect. They can be direct effect, such as patient survival in our 
example, which can be measured directly. They can also be indirect 
effects, such as the changes of ANC values in our example, which were 
affected by treatment and, in turn, affect the outcomes of interest such 
as patient survival. The joint analysis of direct and indirect effects 
to assess the intervention efficacy has been well demonstrated in 
psychiatric research and other related scientific areas. In other words, 
to better understand the complete profile of the treatment effects, 
data needs to be analyzed in more than one aspect.
It is a common practice in clinical trials to estimate the treatment 
effect using the efficacy data, with a limited number of covariates, 
because that is a most direct and conventional approach to gauge 
the effect. However, this kind of limited data analysis can sometimes 
miss the more complete picture of how the treatment really works. In 
conventional clinical trial data analysis, efficacy and safety data are 
usually analyzed separately. However, as we have shown in this article, 
joint analysis of these variables can reveal extra information about the 
treatment and lead to a better understanding of the treatment effect, 
which cannot usually be shown by the separate analysis. 
Statistical methodologies in joint modeling analysis of 
longitudinal and event data has been an area of active research. 
Likelihood and Bayes methods to estimate the model parameters have 
both been proposed to address the mixed effects with measurement 
errors. Parametric and semi-parametric methods have also been 
proposed to test various hypotheses. By taking advantage of these 
existing methods, one can obtain a more comprehensive profile of 
the treatment effects. 
In this paper, we only address the continuous longitudinal data 
with linear mixed effect models; however, similar research can also 
be carried out to incorporate other clinical data which is discrete in 
nature such as the disease severity or patient’s physical functioning 
ability. In addition, the joint model methods can also be extended 
to address the issues of multiple endpoints in clinical trials and 
patient population heterogeneity so that the medical practice can be 
Figure  9: Comparison of random effects between groups.
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individualized to achieve optimal treatment effect. These topics and 
the potential proposals for analysis will be the focus of our continuing 
research. 
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